Literature DB >> 6108394

Infection with Mycoplasma hominis in postpartum fever.

R Platt, J S Lin, J W Warren, B Rosner, K C Edelin, W M McCormack.   

Abstract

A follow-up of 535 patients after vaginal delivery showed that 9% had a fever of 37.7 degrees C or greater, and 2% had a fever of 38 degrees C or more, on two days. The commonest cause of both categories of fever was Mycoplasma hominis infection as defined by a fourfold or greater rise in mycoplasmacidal antibody titre. Among women for whom sera were available this agent caused 50% (14/28) of all fevers and 71% (5/7) of the higher fevers. Absence or low titre (< 1:8) of antibody against M. hominis was the strongest single predictor of otherwise unexplained fever (16/40 patients with low antibody titre were febrile vs 7/50 with high antibody titre, p < 0.01). Among women with absent or low antibody titres, both rise in titre of antibody to this organism and lochial colonisation by it were significantly associated with fever (p < 0.001, p < 0.025, respectively). Standard microbiological and clinical techniques identified probable causes in only 18% (5/28) of all fevers and 29% (2/7) of higher fevers. Patients who had postpartum infection caused by M. hominis remained in hospital 31% longer than the non-infected patients (4.57 vs 3.49 days, p < 0.001). Low antibody to and lochial colonisation with M. hominis occurred together in 17% of patients, who accounted for 71% of all higher fevers. Since these risk factors for postpartum fever can be identified before delivery, prophylactic measures applied selectively to women with these risk factors may prevent a large proportion of postpartum fevers and the excess hospital stay associated with them.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6108394     DOI: 10.1016/s0140-6736(80)92479-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  9 in total

1.  Polymerase chain reaction versus culture for detection of Ureaplasma urealyticum and Mycoplasma hominis in the urogenital tract of adults and the respiratory tract of newborns.

Authors:  M Abele-Horn; C Wolff; P Dressel; A Zimmermann; W Vahlensieck; F Pfaff; G Ruckdeschel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-07       Impact factor: 3.267

Review 2.  The role of urogenital tract infections in the etiology of preterm birth: a review.

Authors:  J Martius; T Roos
Journal:  Arch Gynecol Obstet       Date:  1996       Impact factor: 2.344

3.  Near fatal puerperal fever due to Mycoplasma hominis.

Authors:  M J Young; R A Cox
Journal:  Postgrad Med J       Date:  1990-02       Impact factor: 2.401

4.  Long-term survival and intracellular replication of Mycoplasma hominis in Trichomonas vaginalis cells: potential role of the protozoon in transmitting bacterial infection.

Authors:  Daniele Dessì; Giuseppe Delogu; Eleonora Emonte; Maria Rosaria Catania; Pier Luigi Fiori; Paola Rappelli
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

5.  Isolation of Mycoplasma hominis from a brain abscess.

Authors:  X Zheng; D A Olson; J G Tully; H L Watson; G H Cassell; D R Gustafson; K A Svien; T F Smith
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

6.  Detection of Mycoplasma hominis septicemia by radiometric blood culture.

Authors:  M F Smaron; S Boonlayangoor; C H Zierdt
Journal:  J Clin Microbiol       Date:  1985-03       Impact factor: 5.948

7.  In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.

Authors:  K B Waites; G H Cassell; K C Canupp; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

8.  Mycoplasma hominis septicemia.

Authors:  P C DeGirolami; S Madoff
Journal:  J Clin Microbiol       Date:  1982-09       Impact factor: 5.948

9.  First report of Sneathia sanguinegens together with Mycoplasma hominis in postpartum prosthetic valve infective endocarditis: a case report.

Authors:  Iva Kotaskova; Petr Nemec; Martina Vanerkova; Barbora Malisova; Renata Tejkalova; Marek Orban; Vita Zampachova; Tomas Freiberger
Journal:  BMC Infect Dis       Date:  2017-08-14       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.